Pegasys patients
Common Questions and Answers about Pegasys patients
pegasys
RHHBY), will continue for the remaining 300 genotype 1 and 4 patients in the ongoing phase 2b trial of RG7128, a first-in-class nucleoside analog polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection.
10 × upper limit of normal (ULN), bilirubin 10 × ULN) plus Pegasys (180 μg/kg/week, when ALT was 5–10 × ULN) for 24 weeks. Thirteen HBeAg-negative patients (Group 2) had the same protocol for 48 weeks. In both groups, entecavir was then discontinued 14 days after the initiation of Pegasys. The results were compared, respectively, to 35 HBeAg-positive patients (Group 3) and 24 HBeAg-negative patients (Group 4), all with ALT > 5 × ULN, under continual entecavir monotherapy.
For example, instead of having 15% chance of cure with pegasys alone, one could have maybe 20% (or 25%) chances of cure if pegasys would be combined with 520.
Pegasys can cause substantial side effects though...pegasys + 520 could be even tougher on side effects....so the question is how much one would be willing to take a risk to get to a cure.
Above is just my own estimate (based also on consultation with studyforhope, and the fact that 520 can lower hbsag just by 0.
* A fixed-dose induction (360 mcg) of PEGASYS given once every week for the first 12 weeks then the standard 180 mcg dose of PEGASYS for the following 36 weeks. Patients will also receive the standard dose of ribavirin (1,000-1,200 mg daily) for the full 48 week treatment period.
* The standard 180 mcg dose of PEGASYS for 48 weeks plus a 1,400-1,600 mg daily ribavirin dose for the full 48 week treatment period.
1. Is it Pegasys first then add Entecavir or Entecavir then add Pegasys or Pegasys and Entecavir together? Which one you think is best?
2. Also shouldn't we start with IFN first then if IFN doesn't work then we take Pegasys?
After completing 4 weeks of the triple combination regimen and a follow-up period of four weeks of Pegasys plus Copegus, all patients will then receive 40 weeks of open-label standard of care dosing under a separate protocol. Results from the 500mg and 1500mg dose cohorts in 50 treatment-naïve patients chronically infected with HCV genotype 1 indicated:
* Following 4 weeks of treatment with R7128 1500mg BID with Pegasys plus Copegus, patients achieved a mean 5.
Profound increases in anti-HBV antibodies or immune function were observed in all patients with as few as 6-10 weeks of combination treatment. All patients have achieved HBV antibody levels seen in healthy patients after vaccination with a total of 12 weeks of combination treatment and many patients have achieved antibody titers > 1000 mIU / ml. In 8 out of 9 patients who have achieved this therapeutic vaccine-like response, they continue to control their viral infection off treatment.
I was wondering if anyone else here was considered "high risk" for treatment (the "typical" treatment w/ pegasys (interfuron) and copegasys (ribaviron) and what their experience has been with both access to Doctors willing to try the therapy with them being "high risk" patients, and the therapy itself.
Hyperglycemia, hypoglycemia, and diabetes mellitus have been observed to develop in patients treated with PEGASYS. Patients with these conditions at baseline who cannot be effectively treated by medication should not begin PEGASYS therapy. Patients who develop these conditions during treatment and cannot be controlled with medication may require discontinuation of PEGASYS therapy.
I start pegasys in July. Are the side effects really bad? I know everyone is different.. Do most people lose some of their hair? I just wanted info from someone that has been on this.
I was wondering if there have been any studies comparing Pegasys and Pegintron, and if one has better SVR numbers than the other or was more tolerable.
I am new here so I hope I am posting this in the correct forum.
If you are talking about Hepatitis C treatment, Pegasys is NOT given by itself for treatment naive patients. Pegasys is given in conjunction with Ribavirin for Genotype 2 and Genotype 3 patients. Pegasys is given in conjunction with Ribavirin and a Protease Inhibitor (either Incivek or Victrelis) for Genotype 1 patients.
"Due to the intensity and major side effects of the Incivek, it has been advised to start with the interferon/ribavirin treatment.
Recommended
